Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitroMicrobiology Published on 2021-04-302022-10-31 Journal: Frontiers in Microbiology [Category] COVID-19, [키워드] administration anti-malarial drug anti-SARS-CoV-2 Anti-SARS-CoV-2 Activity antiviral activity antiviral potency approved calu-3 cells caused Cell cells Clinical efficacy Combined compounds Concentration coronavirus coronavirus 2 Coronavirus disease 2019 COVID-19 cumulative demonstrated dosage drug effective drug highest identify in vitro Infection inhibit inhibited inhibitor lung malaria mathematical mefloquine nelfinavir patients potent predicted Prevent public health reduce Replication reported repurposing respiratory SARS-CoV-2 screened severe acute respiratory syndrome-related coronavirus 2 standard treatment synergistic tested Treatment viral dynamics viral entry Viral load virus elimination [DOI] 10.3389/fmicb.2021.651403 PMC 바로가기 [Article Type] Microbiology
Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10–nsp16 Complex of SARS-CoV-2SARS-CoV-2의 nsp10–nsp16 복합체 형성을 폐지하기 위한 매우 강력한 천연물에 대한 분자 시뮬레이션 기반 조사Article Published on 2021-04-142022-09-10 Journal: Biomolecules [Category] SARS, 치료기술, 치료제, [키워드] addition African antiviral drugs best binding affinity binding energy calculated complex Compound compounds conformational database demonstrated disrupt drug interaction Drug interactions feature Formation functional genkwanin inhibit innate immune system Interaction Interface residues investigation life cycle molecular molecular dynamic simulation molecular dynamics Molecular mechanics molecules mRNA natural natural product non-structural protein North nsp10 nsp10–nsp16 complex path potent product risk SARS-CoV-2 SARS-CoV-2 life cycle screened selected Side effects stability stable complex surface area Viral [DOI] 10.3390/biom11040573 PMC 바로가기 [Article Type] Article
Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial PeptoidsArticle Published on 2021-03-312022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] activity Affect Air-liquid interface AMP AMPs antimicrobial antimicrobial peptide Antiviral antiviral activity Antiviral agents antiviral drug antiviral drugs antivirals appear approach Bioavailability candidate caused clinical development COVID-19 cryo-EM cytotoxicity effective epithelial cells examined Factors glycine Herpe host cell membranes HSV-1 in vitro incubated Infection infections LL-37 mechanism membrane disruption molecular feature oligomers peptides Peptoid peptoids potent primary culture Proteases Safe SARS-CoV-2 shown stability treat unique viral envelope viral particle virus viruses Visualization [DOI] 10.3390/ph14040304 PMC 바로가기 [Article Type] Article
Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Based Novel Epitopes Induce Potent Immune Responses in vivo and Inhibit Viral Replication in vitroImmunology Published on 2021-03-262022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, SARS, [키워드] ACE2 acute respiratory syndrome Analysis angiotensin-converting enzyme 2 antiviral activity binding candidate cellular immune responses coronavirus coronavirus 2 develop domain domains effort epitope functional heptad repeat host cell humoral immune response implication in vitro in vivo Infection inhibit inhibitors inhibitory effect initiate murine model N-terminal domain novel NTD peptide peptides potent RBD receptor receptors Region replication of SARS-CoV-2 respiratory response responsible S glycoprotein S1 subunit SARS-CoV-2 shown spike spike (S) glycoprotein spike glycoprotein Spike-based vaccine subunits the receptor-binding domain the SARS-CoV-2 therapeutic Trimers Vaccine virion virus virus entry wild-type virus [DOI] 10.3389/fimmu.2021.613045 PMC 바로가기 [Article Type] Immunology
Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing ScreenPharmacology Published on 2021-03-252022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] animal model Antiviral antiviral activity antivirals approved blocked cathepsin inhibitors Chloroquine Clinical management clinical trials Clinical use clinically Combination Compound Coronavirus disease 2019 COVID-19 Cytopathic effect decrease derivatives did not reduce Diseases displaying drug drug combinations Effect effective Efficacy identification identify in vitro Infection inhibit SARS-CoV-2 inhibitory interferon Plitidepsin potent proportion reduced Remdesivir repurposing SARS-CoV-2 SARS-COV-2 infection Screen screened synergy tested therapy Treatment variety viral entry viral replication virus viruses [DOI] 10.3389/fphar.2021.646676 PMC 바로가기 [Article Type] Pharmacology
Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19Article Published on 2021-03-222022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adjuvant antibody average binding C-terminal domain candidate Containing COVID-19 COVID-19 infection Day distribution domain Efficacy elicit heptad repeat IC50 immunized immunodominant immunogen induced linear epitope mice monoclonal antibody Neutralization antibody Neutralizing antibodies Neutralizing titer potent Prevent Protein pseudo-virus RBD recombinant regions Safe spike Structure Support tested the RBD trimeric Vaccine vaccine candidate [DOI] 10.3390/vaccines9030296 PMC 바로가기 [Article Type] Article
Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen수용체 결합 도메인 기반 면역원을 사용한 SARS-CoV-2에 대한 강력하고 내구성 있는 중화 항체 유도Comparative Study Published on 2021-03-112022-09-12 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] adjuvant Against animal antibody Antibody avidity Antibody Response Antibody titer Antibody titers B-cell epitope cause COVID-19 disease Effect effective Efficacy examined glycoprotein immune system immunized immunogen IMPROVE induction infectious viruses intraperitoneally mice mortality rate NAb neutralization titer neutralizing antibody novel Betacoronavirus observation period pandemic potent Protective Protein public health systems RBD RBD antigen Receptor binding domain regimen Result Safe SARS-CoV-2 severe pneumonia subunit the RBD Vaccine vaccine candidate zoonosis [DOI] 10.3389/fimmu.2021.637982 PMC 바로가기 [Article Type] Comparative Study
Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding DomainVaccines and Antiviral Agents Published on 2021-03-032022-10-30 Journal: Journal of Virology [Category] COVID-19, [키워드] ACE2 affinity alpaca angiotensin-converting enzyme 2 anti-SARS-CoV-2 antibodies antibody approved binding caused cellular COVID-19 COVID-19 vaccine Critical diagnostic reagent dose effective entry of SARS-CoV-2 hetero-bivalent high stability homodimer IgG1 immunized Interaction nanobody neutralization Neutralizing nonoverlapping epitope potent Protein RBD RBD binding RBD-ACE2 RBD-specific antibody SARS-CoV-2 SARS-CoV-2 RBD significantly higher spike stability targeting the receptor-binding domain the Spike Vaccine development [DOI] 10.1128/JVI.02438-20 PMC 바로가기 [Article Type] Vaccines and Antiviral Agents
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans인간의 급성 SARS-CoV-2 감염에 대한 항체 반응의 범위와 기능Research Article Published on 2021-02-262022-08-13 Journal: PLoS Pathogens [Category] Biochemistry, MERS, 진단, 치료법, [키워드] ACE2 ACE2-blocking response acute SARS-CoV-2 infection acute viral infection analysed anti-non-RBD S1 Anti-RBD antibodies Anti-RBD antibody Anti-RBD MAb Anti-RBD MAbs anti-receptor-binding domain anti-S2 Anti-spike anti-spike MAbs antibody Antibody Response Antibody responses Antibody-mediated immunity average Betacoronavirus binding blockade blocked clone Clusters combinations Complete COVID-19 outbreak COVID-19 patient cross-react elicited epitope Epitopes expansion Fever FIVE glycoprotein Health Human human coronavirus human coronavirus OC43 humans Humoral response IgG Immunity independent assays mAbs memory B cell memory B cells monoclonal antibody neutralise neutralising Neutralising activity Neutralising Antibodies neutralising antibody neutralising antibody response non-overlapping epitope non-overlapping epitopes non-RBD S1 nucleocapsid offer outbreak Patient peripheral plasmablast response plasmablast plasmablast response plasmablast responses potent Prolonged fever Prophylactic RBD reactive Receptor-binding domain recovered patient Region responses SARS-CoV-2 SARS-COV-2 infection separate cluster sera serological Serological and plasmablast responses serology somatic mutations spike glycoprotein subset tested the RBD the receptor-binding domain therapeutic agent therapeutic agents titre Viral viral infection Virus spike wild-type SARS-CoV-2 [DOI] 10.1371/journal.ppat.1009352 PMC 바로가기 [Article Type] Research Article
Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody단량체, 서브나노몰 친화성 나노바디에 의한 SARS-CoV-2 D614 및 G614 변이체의 임상 분리물의 강력한 중화Article Published on 2021-02-082022-09-01 Journal: Scientific Reports [Category] MERS, 변종, 진단, [키워드] ACE-2 receptor alpaca antibody Antiviral antiviral agent applicability Bacterial bind binding Biochemistry Biotechnology Cell Biology centrifugation Critical D614G variant density gradient density gradient centrifugation develop Diagnosis E. coli G614 variant global effort health systems IC50 immunization immunology include isolate Isolation Molecular biology monomeric nanobodies nanobody neutralization neutralize potent prophylactic measure prophylactic measures Protein RBD reduce regimen required S RBD SARS-CoV-2 SARS-CoV-2 spike protein selected situation spike Spike protein the SARS-CoV-2 therapeutic Treatment wild type [DOI] 10.1038/s41598-021-82833-w PMC 바로가기 [Article Type] Article